Goldman Sachs removes Baxter International (BAX) from its Conviction List and lowers its PT from $83 to $77 but maintains its Buy recommendation. Since the firm added BAX to its Americas CL in August it is off 7.7% versus the S&P 500's 8.5% gain.
Analyst David Roman cites a higher risk profile due to heightened competition in the plasma business.
Investors appear unconcerned. Shares are up a fraction in early trading.